Graves' disease following commencement of alemtuzumab therapy: Case report discussing clinical considerations and possible pathophysiology
Background: Monoclonal antibodies have become a mainstay in treatment of autoimmune and malignant disease. Adverse reactions to antibody therapy are often unpredictable and include endocrinopathies. The monoclonal antibody alemtuzumab, which is licensed for the treatment of MS, induces Graves'...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Journal of Clinical and Translational Endocrinology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214624522000144 |